Clinical Trials Logo

HER2/Neu Negative clinical trials

View clinical trials related to HER2/Neu Negative.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT01575522 Active, not recruiting - Clinical trials for Stage IV Breast Cancer

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Start date: March 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well tivantinib works in treating patients with recurrent or metastatic breast cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01525966 Active, not recruiting - Clinical trials for Stage IIIA Breast Cancer

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Start date: February 15, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well carboplatin and nab-paclitaxel before surgery work in treating patients with triple negative breast cancer that is inflammatory or has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as carboplatin and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

NCT ID: NCT00877500 Active, not recruiting - Clinical trials for Invasive Breast Carcinoma

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

Start date: March 30, 2009
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ixabepilone compared with standard of care works in treating patients with HER2/Neu negative breast cancer that remains after undergoing systemic therapy. Ixabepilone works by blocking cell division which may cause cancer cell death.